Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Assets (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Non-Current Assets for 7 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 18.44% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.4 million through Dec 2025, down 26.64% year-over-year, with the annual reading at $8.8 million for FY2025, 18.44% down from the prior year.
  • Non-Current Assets for Q4 2025 was $8.8 million at Fulcrum Therapeutics, down from $9.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $21.0 million in Q2 2022, with the low at $8.8 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $13.7 million, with a median of $12.7 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 124.02% in 2022, then crashed 32.25% in 2025.
  • Over 5 years, Non-Current Assets stood at $9.0 million in 2021, then skyrocketed by 112.91% to $19.2 million in 2022, then fell by 19.15% to $15.5 million in 2023, then tumbled by 30.33% to $10.8 million in 2024, then fell by 18.44% to $8.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $8.8 million, $9.0 million, and $9.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.